English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12189/12972 (94%)
造訪人次 : 955440      線上人數 : 716
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版

    子社群

    于重元 [19/19]
    劉柯俊 [85/98]
    劉滄梧 [119/125]
    劉界元(2003-2010) [3/3]
    夏和雄(1996-2012) [26/31]
    夏興國 [51/54]
    姜乃榕 [82/94]
    常慧如 [39/44]
    張俊彥 [234/254]
    張光裕 [69/79]
    張憶壽 [104/107]
    張文祥 [52/53]
    張書銘 [89/91]
    彭汪嘉康(1996-2007) [120/126]
    施能耀 [37/43]
    李家惠 [29/29]
    李岳倫 [48/49]
    林素芳 [32/32]
    楊奕馨 [41/42]
    江士昇 [88/90]
    沈哲宏 [14/16]
    洪文俊 [88/88]
    莊雙恩 [82/91]
    蔡坤志 [32/34]
    蔡慧珍 [67/72]
    蘇勇曄 [40/40]
    蘇振良 [24/25]
    郭靜娟 [71/76]
    陳尚鴻 [45/48]
    陳振陽 [72/72]
    陳立宗 [444/511]
    陳美霞(2002-2009) [1/1]
    陳詩政 [2/2]
    陳雅雯 [38/39]
    黃智興 [55/55]
    黃道揚 [26/26]
    丁兆治(2000-2004) [5/5]
    其他 [465/472]
    劉敏(1996-2007) [60/62]
    劉玫英(2004-2006) [2/2]
    吳成文(1996-2008) [53/55]
    曾思文(1997-2007) [4/4]
    李冠德(1997-2004) [4/6]
    林景太(1999-2007) [5/5]
    楊文光(1996-1999) [21/21]
    王全正(1996-2003) [4/4]
    莊聲宏(1997-2004) [11/11]
    詹宗晃(2000-2008) [2/2]
    賴基銘(2004-2008) [41/47]
    阮麗蓉(2000-2006) [6/7]
    陳俊叡(2003-2007) [6/6]
    馬彥英(1997-1999) [1/1]
    黃奇英(2005-2007) [9/10]

    鄰近社群


    分子與基因醫學研究所 [924/967]
    生技與藥物研究所 [833/1011]
    生醫工程與奈米醫學研究所 [1221/1341]
    免疫醫學研究中心 [226/238]
    神經及精神醫學研究中心 [787/809]
    細胞及系統醫學研究所 [758/818]
    感染症與疫苗研究所 [1544/1621]
    群體健康科學研究所 [2881/3011]
    國家環境醫學研究所 [1563/1594]
    國家蚊媒傳染病防治研究中心 [103/105]
    高齡醫學暨健康福祉研究中心 [223/231]
    論壇 [2/2]
    生醫資源中心 [7/7]
    研究生培育合作學程 [190/194]
    核心儀器設施中心 [9/9]
    病理核心實驗室 [14/14]
    實驗動物中心 [9/9]
    行政管理部門 [18/18]

    社群統計


    近3年內發表的文件:338(14.01%)
    含全文筆數:2253(93.41%)

    文件下載次數統計
    下載大於0次:2253(100.00%)
    下載大於100次:2253(100.00%)
    檔案下載總次數:1618126(30.19%)

    最後更新時間: 2024-12-03 03:47

    上傳排行

    資料載入中.....

    下載排行

    資料載入中.....

    RSS Feed RSS Feed
    跳至:
    或輸入年份:
    由新到舊排序 由最舊的開始

    顯示項目226-250 / 2412. (共97頁)
    << < 5 6 7 8 9 10 11 12 13 14 > >>
    每頁顯示[10|25|50]項目

    日期題名關聯
    2022-10-31 PD-L1 expression in high-risk early-stage colorectal cancer-its clinical and biological significance in immune microenvironment International Journal of Molecular Sciences. 2022 Oct 31;23(21):Article number 13277.
    2022-10-30 Multi-omics analysis reveals clinical value and possible mechanisms of ATAD1 down-regulation in human prostate adenocarcinoma Life. 2022 Oct 30;12(11):Article number 1742.
    2022-10-27 A framework for detecting noncoding rare-variant associations of large-scale whole-genome sequencing studies Nature Methods. 2022 Oct 27;19:1599-1611.
    2022-10-23 Real-world comparative effectiveness of nivolumab versus pembrolizumab in patients with unresectable hepatocellular carcinoma Pharmaceutics. 2022 Oct 23;14(11):Article number 2263.
    2022-10-22 Vickers hardness value test via multi-task learning convolutional neural networks and image augmentation Applied Sciences. 2022 Oct 22;12(21):Article number 10820.
    2022-10-20 Reprogramming of sentinel lymph node microenvironment during tumor metastasis Journal of Biomedical Science. 2022 Oct 20;29:Article number 84.
    2022-10-11 Upregulated ubiquitin D is a favorable prognostic indicator for rectal cancer patients undergoing preoperative concurrent chemoradiotherapy OncoTargets and Therapy. 2022 Oct 11;15:1171-1181.
    2022-10-10 Prognostic abilities of pre- and post-treatment inflammatory markers in oral squamous cell carcinoma: Stepwise modelling Medicina. 2022 Oct 10;58(10):Article number 1426.
    2022-10 Chronic mechanical irritation enhances the effect of tobacco and alcohol on the risk of oral squamous cell carcinoma: A case-control study in Argentina Clinical Oral Investigations. 2022 Oct;26(10):6317-6326.
    2022-10 The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma Hepatology International. 2022 Oct;16(5):1137-1149.
    2022-10 Impaired chromatin remodeling predicts better survival to modified gemcitabine and S-1 plus nivolumab in advanced biliary tract Cancer: A phase II T1219 study Clinical Cancer Research. 2022 Oct 3;28(19):4248-4257.
    2022-10 Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma - with emphasis on locoregional therapy for oligoprogression Hepatology. 2022 Oct;76(Suppl.1):S1411-S1412.
    2022-10 An integrated microfluidic device for automated detection of cancer cells from bile for cholangiocarcinoma prognosis MicroTAS 2022 - 26th International Conference on Miniaturized Systems for Chemistry and Life Sciences. 2022 Oct:229-230.
    2022-09-26 Mitochondrial oxidative stress in the tumor microenvironment and cancer immunoescape: foe or friend? Journal of Biomedical Science. 2022 Sep 26;29:Article number 74.
    2022-09-21 Clustering of chromatin remodeling enzymes predicts prognosis and clinical benefit of therapeutic strategy in pancreatic cancer International Journal of Medical Sciences. 2022 Sep 21;19(10):1615-1627.
    2022-09-15 Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma receiving liposomal irinotecan plus 5-fluorouracil and leucovorin American Journal of Cancer Research. 2022 Sep 15;12(9):4267-4278.
    2022-09-13 UMOD mutations in chronic kidney disease in Taiwan Biomedicines. 2022 Sep 13;10(9):Article number 2265.
    2022-09 Beta-glucan therapy converts the inhibition of myeloid-derived suppressor cells in oral cancer patients Oral Diseases. 2022 Sep;28(6):1484-149.
    2022-09 Neuropsychiatric symptoms and mortality among patients with mild cognitive impairment and dementia due to Alzheimer's disease Journal of the Formosan Medical Association. 2022 Sep;121(9):1705-1713.
    2022-09 Multi-kinase inhibitors for the treatment of asymptomatic radioactive Iodine-refractory differentiated thyroid cancer: Global non-interventional study (RIFTOS MKI) Thyroid. 2022 Sep;32(9):1059-1068.
    2022-09 A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma – The Taiwan Cooperative Oncology Group T1217 study European Journal of Cancer. 2022 Sep;173:123-132.
    2022-09 High MT2A expression predicts worse prognosis in patients with urothelial carcinoma Oncology. 2022 Sep;100(9):485-497.
    2022-09 Systemic treatment of advanced unresectable hepatocellular carcinoma after first-line therapy: Expert recommendations from Hong Kong, Singapore, and Taiwan Liver Cancer. 2022 Sep;11(5):426-439.
    2022-09 Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) Annals of Oncology. 2022 Sep;33(7):S565-S566.
    2022-08-28 Injectability, processability, drug loading, and antibacterial activity of gentamicin-impregnated mesoporous bioactive glass composite calcium phosphate bone cement in vitro Biomimetics. 2022 Aug 28;7(3):Article number 121.

    顯示項目226-250 / 2412. (共97頁)
    << < 5 6 7 8 9 10 11 12 13 14 > >>
    每頁顯示[10|25|50]項目

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋